Publications by authors named "L Aceituno"
Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma (HCC) for almost three decades. In recent years, its role has been evolving to include patients with disease burden beyond the widely used Milan criteria. The integration of dynamic biomarkers such as alpha-fetoprotein together with downstaging approaches and tumor evolution after enlistment has allowed the selection of patients most likely to benefit, resulting in 5-year survival rates greater that 70%.
View Article and Find Full Text PDFBackground: Hepatocellular carcinoma (HCC) recurs after liver transplantation (LT) in ~17% of patients. We aimed to retrospectively compare the outcomes of patients treated with different tyrosine kinase inhibitors (TKIs) for recurrent HCC post-LT.
Methods: Patients with recurrent HCC post-LT between 2006 and 2019 were included.
Article Synopsis
- Zinc homeostasis may improve liver function and reduce complications in patients with compensated advanced chronic liver disease, potentially lowering the risk of hepatocellular carcinoma (HCC).
- The ANTICIPATE model will help assess the varying risks of liver-related issues in the diverse group of patients participating in the study.
- This ongoing phase III clinical trial aims to enroll 300 patients to test the effects of zinc acexamate versus a placebo over a 42-month period, with a focus on improving patient prognosis and reducing serious clinical events.
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Clin Genitourin Cancer
October 2024
Introduction: Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Living donor liver transplantation (LDLT) significantly improves survival rates for liver disease patients and decreases wait times for transplants.
- A study of 7,257 LDLT recipients showed a median overall survival of 17 years, with various factors influencing mortality rates identified over time.
- The findings suggest that LDLT is a safe and effective procedure, and survival rates have improved even as patient risk factors have increased, indicating room for further advancements in the field.